Xarelto, a blood thinner used to prevent clots in surgery patients and also to treat irregular heartbeats, has been linked to a growing number of side effects and deaths.
A relatively new drug in the United States (FDA approved in July 2011), Xarelto was cited in 968 cases of suspected side effects leading to 78 deaths in the first eight months of 2013. That was an increase from 750 cases and 58 fatalities in all of 2012.
Kline & Specter, with more than 40 attorneys, five of whom are also highly skilled doctors, has the expertise and experience to litigate Xarelto injury cases. The firm, particularly its Mass Tort department, has been a leading player in successful drug litigation.
Xarelto was developed jointly by the German company Bayer and U.S. manufacturer Johnson & Johnson. The side effect statistics were reported by the German Federal Institute for Drugs and Medical Devices, that country’s equivalent of the U.S. Food and Drug Administration, and later several media outlets.
Xarelto was first approved to prevent blood clots in patients undergoing knee and hip operations and was later expanded for patients with leg and lung blood clots and irregular heartbeats. The drug makers failed to win approval to further expand Xarelto to prevent heart attacks and strokes in patients with histories of cardiac illness.
The anti-clotting pill is considered an important new drug for Bayer, with sales expected to reach more than $2.5 billion annually.